Schizophrenia is a devastating mental illness characterized by symptoms eg hallucinations, disorganized thinking, loss of goal-directed behaviors and deterioration in social role functioning.
Positive or psychotic symptoms are delusions, hallucinations, and distorted perceptions.
Negative symptoms include flat or blunted emotions, lack of motivation or energy, lack of pleasure or interest in things, and limited speech.
Disorganized symptoms are confused thinking, disorganized speech and behavior.
Cognitive symptoms include impairment in attention verbal fluency memory, and executive functioning.
Continuous primary care follow-up during the transition from adolescence to young adulthood could reduce the risk of mental illness-related hospitalizations post-transition in individuals with severe mental illness, according to a Canadian study.
Relapse in schizophrenia appears to contribute to increased treatment resistance, with a recent study showing that response to antipsychotic medication is reduced or delayed in patients who relapse after effective treatment of the first episode.
Children born to parents with schizophrenia are at increased risk of developing a variety of neurological disorders, as well as visual and hearing disorders, at an early age, a study has found. The same is true for those born to parents with a major depression.
Antipsychotic drug treatment appears to be less effective in patients with higher polygenic risk score (PRS) for schizophrenia, suggests a study. PRS burden appears to be useful as a prognostic biomarker.
Major depressive disorder (MDD) commonly occurs in schizophrenic patients and is associated with several factors including paranoid delusions and avolition, a study reports. Moreover, although antidepressants produce improvements in symptom level, many patients remain depressed despite treatment.
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.